home / stock / igc / igc news

IGC News and Press, IGC Pharma Inc.

Stock Information
Company Name: IGC Pharma Inc.
Stock Symbol: IGC
Market: NYSE
Website: igcpharma.com
Menu
Get IGC Alerts

News, Short Squeeze, Breakout and More Instantly...
IGC - IGC Pharma to Showcase AI Portfolio at AAIC 2026, Including AHA Platform That Reduced Alzheimer's Data Harmonization Time by 90% in Representative Workflow

Seven presentations highlight patent-pending agentic automation, speech-based cognitive models, EHR mining, and predictive analytics designed to support Alzheimer's discovery and clinical development POTOMAC, MD / ACCESS Newswire / July 9, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC...
IGC - IGC Pharma CEO, finance chief buy $1.15M of common stock

2026-07-07 09:23:48 ET More on IGC Pharma IGC Pharma GAAP EPS of -$0.02 in-line, revenue of $0.32M beats by $0.09M Seeking Alpha’s Quant Rating on IGC Pharma Historical earnings data for IGC Pharma Financial information for IGC Pharma Read th...

IGC - IGC Pharma CEO and Principal Financial Officer Purchase More Than $1.15 Million of Common Stock Directly from the Company

Senior management elects restricted common stock at $0.27 per share in lieu of repayment of amounts owed, including more than $552,362 of personal cash previously advanced to IGC POTOMAC, MD / ACCESS Newswire / July 7, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), ...

IGC - IGC Pharma's AHA Agentic AI Platform Reduces Alzheimer's Data Harmonization Time by 90% in Representative Workflow

Patent-Pending Multi-Agent Architecture Targets Fragmented Biomedical Data and Expands Toward Imaging, Omics, and Broader Health-Data Applications Ahead of Planned AAIC 2026 Demonstration in London POTOMAC, MD / ACCESS Newswire / June 23, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC...
IGC - IGC Pharma Reaches Previously Disclosed 146-Patient Enrollment Target in Phase 2 CALMA Trial, Advancing Toward Topline Analysis

Company Continuing Limited Over-Enrollment Activities to Account for Attrition and Support Robust Modified Intent-to-Treat, End-of-Treatment and Exploratory Analyses POTOMAC, MD / ACCESS Newswire / June 11, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company") today announc...

IGC - Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.50, Citing Clinical Progress and 2026 Catalysts

POTOMAC, MD / ACCESS Newswire / June 9, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, today announced that Ascendiant Capital Markets has issued an updated equity research report on ...

IGC - IGC Pharma Adds Mount Sinai Clinical Site as CALMA Trial Advances Toward Completion and Topline Analysis

Approximately 80% of target participants have completed trial participation, strengthening momentum toward database lock and topline analysis POTOMAC, MD / ACCESS Newswire / June 2, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company") , a clinical-stage biotechnology comp...
IGC - IGC Pharma GAAP EPS of -$0.02 in-line, revenue of $0.32M beats by $0.09M

2026-05-19 17:32:03 ET More on IGC Pharma Seeking Alpha’s Quant Rating on IGC Pharma Historical earnings data for IGC Pharma Financial information for IGC Pharma Read the full article on Seeking Alpha For further details see: IGC Pharma GAA...

IGC - IGC Pharma Reports First Quarter 2026 Financial Results with CALMA Phase 2 in the final stage, with 80% Enrollment

- Continued Advancement of CALMA Phase 2 Trial - POTOMAC, MD / ACCESS Newswire / May 19, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company") , a clinical-stage biotechnology company developing therapeutics and artificial intelligence ("AI-enabled") tools for Alzheimer's ...

IGC - IGC Pharma to Present Tau-PET Biomarker Research at 2026 Global Tau Conference

Research highlights advanced imaging analytics that may support Alzheimer's disease monitoring, patient stratification, and future therapeutic development. POTOMAC, MD / ACCESS Newswire / May 15, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company") , a clinical-stage biot...
Next 10